DNA-binding protein inhibitor ID-1 (ID1) mRNA (ID1)

DNA-binding protein inhibitor ID-1 (ID1) mRNA encodes a protein that acts as a dominant-negative regulator of basic helix-loop-helix (bHLH) transcription factors (UniProt P41128). By sequestering these factors, ID1 prevents their binding to DNA, thereby inhibiting cell differentiation and promoting a proliferative, undifferentiated state (PubMed: 22964524). ID1 is frequently overexpressed in various cancers, including breast, lung, and glioblastoma, where it facilitates epithelial-mesenchymal transition (EMT), metastasis, and chemoresistance (PubMed: 28341798). Therapeutic strategies targeting ID1 mRNA, such as antisense oligonucleotides (ASOs) and siRNA, aim to reduce ID1 protein levels to restore bHLH-mediated differentiation and induce apoptosis in cancer cells (PubMed: 18025276). Additionally, certain small molecules like Cannabidiol have been shown to downregulate ID1 expression, offering a potential pharmacological approach to inhibiting this pathway (PubMed: 18025276). Despite its potential, therapeutic targeting of ID1 mRNA faces challenges such as ensuring specific delivery to tumor cells and avoiding adverse effects on normal stem cell populations (PubMed: 26307680).

Other names

Inhibitor of DNA binding 1Inhibitor of differentiation 1bHLHb24ID1 mRNA

Degradation of ID1 mRNA via antisense oligonucleotides (RNase H-mediated) or RNA interference (RISC-mediated) to prevent translation of the ID1 protein; transcriptional downregulation by small molecules.